Scleroderma Therapeutics Market Size, Share and Trends 2026 to 2035

Revenue, 2025

USD 2.74 Bn

Forecast Year, 2035

USD 4.48 Bn

CAGR, 2026 - 2035

5.04%

Report Coverage

Global

What is the Scleroderma Therapeutics Market Size?

The global scleroderma therapeutics market size is calculated at USD 2.74 billion in 2025 and is predicted to increase from USD 2.88 billion in 2026 to approximately USD 4.48 billion by 2035, expanding at a CAGR of 5.04% from 2026 to 2035.

Scleroderma Therapeutics Market Key Takeaways

• North America dominated the scleroderma therapeutics market with the largest market share of 47% in 2025.
• Asia Pacific is projected to grow at a CAGR of 7.82% during the forecast period.
• By drug class, the immunosuppressors segment contributed the highest share of 29% in 2025.
• By drug class, the endothelin receptor antagonist segment is expected to grow at a CAGR of 5.72% during the forecast period.
• By indication, the systemic scleroderma segment held a major market share of 78% in 2025.
• By indication, the localized scleroderma segment is anticipated to grow at the highest CAGR during the forecast period.

What are Scleroderma Therapeutics?

Scleroderma is a rare condition in which overproduction of collagen causes a hardening of the skin, and in some cases, blood vessels and internal organs also get affected. The disease is four times more common in women than men. The growing prevalence of scleroderma disease is driving growth in the development of novel treatment solutions. The scleroderma therapeutics market is attributed to North America and Europe due to the increased prevalence of scleroderma in these regions. Moreover, expanded healthcare infrastructure and aging populations are fueling demands for effective treatments for sclerodermas. Growing investments by governments and pharmaceutical companies for the development of innovative treatments like antifibrotic agents.

Moreover, raising awareness about rare diseases means finding ways to cure diseases and prepositions. Growing focus on health and wellness, as well as government and regulatory initiatives for healthcare R&D and pharmaceutical sectors, are expected to boost the scleroderma therapeutics market in the upcoming period. Ongoing investments for stem cell and gene researchers are projected to develop cutting-edge solutions for scleroderma. Additionally, ongoing developments in innovative therapies and technology are likely to shed light on the industry's growth.

What is the use of AI in the scleroderma therapeutics industry?

Artificial intelligence is taking the growth of the scleroderma therapeutics market to light by providing disease monitoring and diagnosis abilities. AI can analyze large databases and previous discoveries, which makes it easier for researchers to understand previous theories and reduce time investments. AI is able to provide all optimizing management processes as well as cost and time associated with research and manufacturing, which helps to build a better outlook plan.

AI allows for the generation of patient history, medical conditions, and genetic profiles, which helps to understand targeted treatments, and it becomes easier to develop effective treatments in the scleroderma therapeutics market. It is able to provide personalized medicine solutions by analyzing patient-relevant data and actual needs. The utilization of AI is making it easier to understand the manifestation and progression of the disease in the patient body. For instance, the utilization of AI in high-resolution computed tomography (HRCT) for treatments of systemic sclerosis is done with an understanding of lung disease. The benefits of AI in streamlining clinical trials , minimizing cost, and developing novel therapies are increasing the adoption of AI in the research and pharmaceutical sectors.

Scleroderma Therapeutics Market Growth Factors

• The rising prevalence of scleroderma disease in regions like North America and Europe is driving the growth of the market.
• Aging populations are the key factors contributing to the market growth due to the growing prevalence of disease among the elderly population and demands for scleroderma therapeutics.
• Expanding urbanization and changing lifestyles are the main reasons for inviting rare diseases like scleroderma.
• The increased awareness of disease among patients and healthcare professionals is shifting market expansions.
• Growing government focus and initiatives toward healthcare and the R&D sector are encouraging the development of innovative treatments, leading to boosting the scleroderma therapeutics market expansion.
• Growing pharmaceutical investments for research and development of novel therapies are highlighting the market potential.
• The expansion of treatment options, including oral, injectable, and topical, is making it easy to adopt novel advanced treatments.
• The adoption of advanced technologies like biomarker testing, imaging, 3D printing, and stem cells is holding market potential.

Scleroderma Therapeutics Market Outlook

[[market_outlook]]

Market Scope

Market Dynamics

Drivers

Increased research and development investments

The increasing prevalence of rare and critical diseases is prompting government and non-government bodies to prioritize investments in research and development of novel scleroderma therapeutics market solutions. Moreover, pharmaceutical biotechnology companies are also investing in research and development of cutting-edge treatments. With growing awareness of the disease among medical professionals and patients, the demand for effective treatment options has increased, leading to the encouraging development of innovative solutions.

Investment in research and development has led to the delivery of advanced therapies like immunosuppressants, antifibrotic agents, biologics , gene therapies , stem cells, and other small molecules, which help to manage the disease progress and also help to boost the immunity power of patients in the scleroderma therapeutics market. Moreover, the growing collaboration between pharmaceutical and biotechnology industries with universities and research teams is encouraging government and regulatory frameworks for further investments in the sectors.

Restraints

Limited understanding of scleroderma's pathophysiology

The limited understanding of pathophysiology is still a major restraint for the growth of the scleroderma therapeutics market. It is hard to identify effective targets to understand the diagnostics due to the involvement of immune cells by sclerodermas. Additionally, disease involves multiple pathways, which makes it hard for professionals to understand which pathway they should target. The development of antifibrotic treatments is still to be done due to a limited understanding of the mechanism of fibrosis. In recent studies, histopathological changes have been seen, which makes it more critical to understand the mechanisms of fibrosis. The lack of understanding of pathophysiology is hampering the development of effective treatments.

Opportunities

Developments of new biomarkers

The developments of novel biomarkers, like genetic, protein , and imaging biomarkers, hold potential in the scleroderma therapeutics market. The need for early detection and personalized treatments is leading to the development of genetic biomarkers. Similarly, protein biomarkers are being developed to monitor disease progress and response to treatments in the patient's body. Imaging biomarkers are important to assess skin and internal organ involvements. Imaging biomarkers like ultrasound and Magnetic Resonance Imaging are in high demand.

Biomarkers not only help to understand disease conditions and treatment processes but also help to develop novel scleroderma therapeutics market solutions. The need to improve patient outcomes is driving demands for biomarkers. Moreover, the growing investment by pharmaceutical and biotechnology companies in biomarker research and development is likely to transform the market. Additionally, government funding, support, and academic researchers are likely to contribute to the adoption and development of novel biomarkers to enhance treatment options for scleroderma.

Segment Insights

[[segment_insights]]

Regional Insights

[[regional_insights]]

Scleroderma Therapeutics Market Companies

[[market_company]]

Other Major Key Players

• Bayer AG
• Sanofi
• Cytori Therapeutics Inc.
• Akashi Therapeutics
• Prometic Life Sciences

Latest Announcements by Industry Leaders

• In November 2024, Dr. Luke Evnin, Chairman of the Board for the SPF, talked about the Scleroderma Research Foundation's launching of CONQUEST; “The introduction of the CONQUEST trial reflects the spectacular milestone in companies' efforts to improve scleroderma research.”
• In September 2024,” Darren Kelly, PhD, CEO, founder, and managing director of Certa, talked in a company press release about receiving the INN name for Certa Therapeutics' oral drug candidate; “Getting an INN for companies like oral, lead drug candidate as asengeprast, is the most important step in the development of this novel important therapy.”

Recent Developments in Scleroderma Therapeutics

• In November 2025, Sandoz launched TYRUKO. TYRUKO is an advanced biosimilar designed for treating patients suffering from multiple sclerosis.
  (Source: www.sandoz.com )
• In June 2025, Cabaletta Bio, Inc. launched a new range of medicines for treating scleroderma. This new range of medication is designed for the consumers of the U.S.
  (Source: www.cabalettabio.com )

Segments Covered in the Report

[[segment_covered]]